Novo Nordisk A/S’s (NVO) “Neutral” Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of Novo Nordisk A/S (NYSE:NVO) in a research report sent to investors on Tuesday, Marketbeat Ratings reports.

NVO has been the topic of several other research reports. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, Citigroup initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. Six analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Down 2.5%

Shares of NYSE NVO opened at $38.64 on Tuesday. Novo Nordisk A/S has a 12-month low of $38.36 and a 12-month high of $93.80. The firm’s 50-day simple moving average is $53.35 and its 200 day simple moving average is $53.14. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The company has a market cap of $172.52 billion, a price-to-earnings ratio of 11.13 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the business. SG Trading Solutions LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $401,000. Sunbelt Securities Inc. increased its position in shares of Novo Nordisk A/S by 1.5% during the fourth quarter. Sunbelt Securities Inc. now owns 21,316 shares of the company’s stock worth $1,085,000 after acquiring an additional 323 shares in the last quarter. White Knight Strategic Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $732,000. Hamilton Wealth LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at $545,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Novo Nordisk A/S in the 4th quarter worth $41,000. Institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Phase‑2 China trial: a joint Novo program (UBT251, a triple GLP‑1/GIP/glucagon agonist) reported up to ~19.7% mean weight loss at 24 weeks with a tolerable safety profile — a constructive signal for long‑term pipeline diversification beyond semaglutide. UBT251 Phase 2 China results
• Neutral Sentiment: Some investors and bullish analysts argue the market is overreacting to a single head‑to‑head miss and point to continued Wegovy/Ozempic international growth and upcoming oral options as offsetting factors. Seeking Alpha perspective
• Negative Sentiment: REDEFINE‑4 Phase‑3 miss: CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide in an open‑label head‑to‑head, raising doubts about Novo’s ability to defend obesity market share against Lilly’s lead. This clinical setback is the primary catalyst for the recent sell‑off. CagriSema trial coverage
• Negative Sentiment: Price cuts: Novo announced plans to reduce U.S. list prices for Wegovy and Ozempic (up to ~50%, with headline pricing around $675/month starting Jan 2027), a move intended to improve access but likely to pressure list‑price revenue and margins. Price cut report
• Negative Sentiment: Analyst reactions and downgrades: multiple banks trimmed ratings/targets after the trial news, and coverage turned more cautious — amplifying selling pressure and repricing expectations for growth. Analyst downgrades coverage
• Negative Sentiment: Legal/investor scrutiny: law‑firm notices and investor inquiries have appeared following the clinical disclosure, representing an added reputational and potential financial overhang. Investor investigation notice

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.